All Type of News
The substance patent of the DDP-4 diabetes treatment ‘Januvia’ has been the main target
Chong Kun Dang, Jeil Pharmaceutical and Hanmi Pharm have recently filed a nullity trial for the substance patent of Januvia.
As working on approval procedures, these pharmaceutical companies will be the first ones la...
Sales of listed pharmaceutical companies increased 11.5% in average, stating “We overcame the En Bloc Drug Price Reduction”
As sales of listed pharmaceutical companies increased 10% up last year, it is analyzed that they overcame hardships of the En Bloc Drug Price Reduction striking the pharmaceutical industry in 2012.
According to the Y...
It is about to establish a compass of the KMA’s policies, the ‘KMA POLICY’
Since the beginning of 2014, the Korean Medical Association (KMA) has worked on establishment of the ‘KMA POLICY’, benchmarking the AMA POLICY. It is expected that the association will complete establishing the system...
Navipharm is rushing on patent challenges while Handok Teva had its debut
Competition to acquire the Priority Sale Item Approval Rights has been activated among generic pharmaceutical companies. The IP R&D company, Navipharm, has made sudden movements, facing the ‘Patent Linkage System’.
M...
Although the supply of ‘Tylenol ER’ increased, it still is out of stock
Janssen Korea announced to increase an output of Tylenol ER in March. The company judged that the company has had a trouble supplying the product to pharmacies and decided to respond to it through the increase of the ...
The long expiration date of Tamiflu seems way too long
Tamiflu has been an issue due to its long expiration date compared to other pharmaceutical products. Vice president Chang-wook Choi of the Busan Pharmaceutical Association unveiled a picture of Tamiflu that has recent...
LG Life Sciences will target $500 million with its first domestic diabetes treatment ‘Zemiglo’LG Life Sciences will speed up on expanding its first domestic diabetes treatment ‘Zemiglo (generic name: gemigliptin)’ to global markets.
According to the company, Zemiglo, la...
|
Domestic pharmaceutical companies are catching up multinational ones in the KRW 600 billion domestic hyperlipidemia treatment market
In the hyperlipidemia treatment market, multinational and domestic pharmaceutical companies are having fierce competitions.
Last year, the size of the domestic hyperlipidemia treatment market was KRW 600 million (80%...
The largest cash dividends, KRW 3.2 billion, will be given to Dong-yeon Kim while Jang-han Lee and Il-sup Huh will receive KRW 2 billion and KRW 1.8 billion, respectively
Among owners of list pharmaceutical companies, president Dong-yeon Kim of Bukwang Pharm will receive the largest cash dividends from the 2014 settlement of accounts.
President Jang-han Lee of Chong Kun Dang and presi...
Will the era of domestic biosimilar successes open?
As the first biosimilar, the Sandoz’s ‘Zarxio (generic name: filgrastim)’, has recently acquired sale approvals in the U.S., biosimilars developed by domestic companies have attracted attention of the industry.
As a ...
